NCT01552694View on ClinicalTrials.gov

Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation

PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions
InflammationMacrophage InfiltrationCardiovascular Disease
Interventions
DRUG

Sitagliptin

Oral, 100 mg/day for 2 months

DRUG

Placebo

oral, matching placebo daily for 2 months

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT01552694 - Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation | Biotech Hunter | Biotech Hunter